Quick Takeaways
- BB BIOTECH AG filed SCHEDULE 13G/A for Agios Pharmaceuticals, Inc. Common Stock (AGIO).
- Disclosed ownership: 6.2%.
- Date of event: 31 Dec 2024.
BB BIOTECH AG - 31 Dec 2024 SCHEDULE 13G/A Report for Agios Pharmaceuticals, Inc. Common Stock (AGIO)
- Filing Manager
- BB BIOTECH AG
- Reporting Manager
- BB Biotech AG
- Symbol
- AGIO
- Shares outstanding
- 56,695,968 shares
- Disclosed Ownership
- 3,515,150 shares
- Ownership
- 6.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 14:35:11 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 13 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BB BIOTECH AG disclosed 6.2% ownership in Agios Pharmaceuticals, Inc. Common Stock (AGIO) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 14:35.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 6.2% | 3,515,150 | 0 | 3,515,150 | /s/ Martin Gubler | Martin Gubler/Signatory Authority | |
| Biotech Target N.V. | 6.2% | 3,515,150 | 0 | 3,515,150 | /s/ Jan Bootsma | Jan Bootsma/Signatory Authority |